1H-苯并咪唑-4-硼酸 | 499769-95-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1H-苯并咪唑-4-硼酸
• 英文名称: (1H-benzo[d]imidazol-4-yl)boronic acid
• 英文别名: 1H-Benzimidazol-4-ylboronic acid
• CAS: 499769-95-8
• 化学式: C₇H₇BN₂O₂
• mdl: MFCD26517700
• 分子量: 161.956
• InChiKey: UNWJCMBQRPPTIH-UHFFFAOYSA-N

物化性质

• 沸点：
  553.7±42.0 °C(Predicted)
• 密度：
  1.42±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.84
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  69.1
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 安全说明：
  S26,S37/39

SDS

Name:	1H-Benzimidazol-4-ylboronic acid 97% Material Safety Data Sheet
Synonym:
CAS:	499769-95-8

Section 1 - Chemical Product MSDS Name:1H-Benzimidazol-4-ylboronic acid 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
499769-95-8	1H-Benzimidazol-4-ylboronic acid	97	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Keep refrigerated. (Store below 4C/39F.) Store in a tightly closed container. Store in a dry area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 499769-95-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 192.9 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H7BN2O2
Molecular Weight: 161.96

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, oxides of boron.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 499769-95-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1H-Benzimidazol-4-ylboronic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 499769-95-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 499769-95-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 499769-95-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1H-苯并咪唑-4-硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 5.0h， 以5%的产率得到6-(1H-benzo[d]imidazol-4-yl)-N-(2-fluorophenyl)-9,10-dihydro-8H-pyrido[1,6-a:2,3-d']dipyrimidin-2-amine
  参考文献：
  名称：

  [EN] KINASE INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DE KINASE ET LEURS UTILISATIONS

  摘要：

  提供了环状亚胺吡啶二烷化合物及其双环衍生物，包括这些化合物的药物组合物，以及使用这些化合物或组合物的方法，例如治疗增殖紊乱疾病的方法，如癌症或肿瘤，或在某些情况下与激酶失调相关的疾病或紊乱，例如但不限于 MAPK、PDGFR、Src、PAKs、c-Kit、EphA2、EphB4、FGFR、Axl 和 c-Met。

  公开号：

  WO2022032071A1
• 作为产物：
  描述：

  4-溴-1H-苯并咪唑 、 联硼酸频那醇酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 、 盐酸 作用下， 以 N,N-二甲基甲酰胺 、 水 为溶剂， 反应 1.17h， 生成 1H-苯并咪唑-4-硼酸
  参考文献：
  名称：

  从麦角灵到吲哚：改进的人类H3受体抑制剂用于发作性睡病的治疗

  摘要：

  麦角灵最近被鉴定为新型的H3受体（H3R）反向激动剂。尽管他们的优化使候选药物在发作性睡病治疗方面具有令人鼓舞的特性，但脑部渗透率仍然很低。为了克服这个问题，麦角灵1（（6a R，9 R，10a R）‐4‐（2‐（二甲基氨基）乙基）‐N‐苯基‐9‐（吡咯烷‐1‐羰基）‐6,6a，8， 9,10,10a-六氢吲哚[4,3- fg ]喹啉-7（4 H）-羧酰胺））被转化为一系列具有高H3R亲和力的吲哚衍生物。通过同时测定它们在小鼠中的脑受体占有率（RO）水平和药效学（PD）效应，对这些新分子进行了分析。这些努力最终导致发现15 m（（R）-1-异丙基-5-（1-（2-（2-甲基吡咯烷酮-1-基）乙基）-1 H吲哚-4-基）吡啶2 （1 H）‐one），其具有理想的特征，显示PD效应与RO有很强的相关性，并且没有可测量的安全系数。通过在大鼠中的脑电图（EEG）测量，证实了其理想的持续时间短。

  DOI：

  10.1002/cmdc.201402418

文献信息

• [EN] METALLO-BETA-LACTAMASE INHIBITORS<br/>[FR] INHIBITEURS DE MÉTALLO-BÊTA-LACTAMASES
  申请人：MERCK SHARP & DOHME

  公开号：WO2016206101A1

  公开（公告）日：2016-12-29

  The present invention relates to compounds of formula I that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

  本发明涉及一种属于金属β-内酰胺酶抑制剂的I式化合物，以及这种化合物的合成和将其与β-内酰胺类抗生素一起用于克服耐药性的用途。
• N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES
  申请人：Chang Edcon

  公开号：US20120220575A1

  公开（公告）日：2012-08-30

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein Ar, R 1 , R 2 , R 3 , G 1 , G 2 , and m are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating inflammatory disorders, cardiovascular disease, cancer, and other conditions associated with PI3Kδ.

  本发明涉及公式1的化合物及其药学上可接受的盐，其中Ar、R1、R2、R3、G1、G2和m在说明书中有定义。本公开还涉及制备公式1化合物的材料和方法，包括含有它们的制药组合物，以及它们用于治疗炎症性疾病、心血管疾病、癌症和与PI3Kδ相关的其他疾病的用途。
• N-substituted oxazinopteridines and oxazinopteridinones
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US09045496B2

  公开（公告）日：2015-06-02

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein Ar, R1, R2, R3, G1, G2, and m are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating inflammatory disorders, cardiovascular disease, cancer, and other conditions associated with PI3Kδ.

  本文揭示了1式化合物及其药学上可接受的盐，其中Ar、R1、R2、R3、G1、G2和m的定义见规范。本文还涉及制备1式化合物的材料和方法，含有它们的制药组合物，以及它们用于治疗炎症性疾病、心血管疾病、癌症和与PI3Kδ相关的其他疾病的用途。
• US2014/275079
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] KINASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE KINASE ET LEURS UTILISATIONS
  申请人：ABM THERAPEUTICS CORP

  公开号：WO2022032071A1

  公开（公告）日：2022-02-10

  Provided are cyclic iminopyridimdine compounds and their bicyclic derivatives, pharmaceutical compositions comprising such compounds, and methods of using such compounds or compositions, such as methods of treating a proliferation disorder, such as a cancer or a tumor, or in some embodiments disease or disorders related to the dysregulation of kinase such as, but not limited to kinases such as MAPK, PDGFR, Src, PAKs, c-Kit, EphA2, EphB4, FGFR, Axl, and c-Met.

  提供了环状亚胺吡啶二烷化合物及其双环衍生物，包括这些化合物的药物组合物，以及使用这些化合物或组合物的方法，例如治疗增殖紊乱疾病的方法，如癌症或肿瘤，或在某些情况下与激酶失调相关的疾病或紊乱，例如但不限于 MAPK、PDGFR、Src、PAKs、c-Kit、EphA2、EphB4、FGFR、Axl 和 c-Met。